Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation Study of DN-101 and Docetaxel
NCT00285675Phase 2Unknown
- Sponsor
- Novacea
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Asentar in castration-resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC), sponsored by Novacea. Status: unknown.
02
Drugs
Asentar
03
Conditions
castration-resistant prostate cancer (CRPC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00285675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00285675.